References
- Mansur A, Radovanovic I. Vascular malformations: an overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapy. Front Neurol 2023; 14: 1-10. doi: 10.3389/fneur.2023.1099328
- Kunimoto K, Yamamoto Y, Jinnin M. ISSVA Classification of vascular anomalies and molecular biology. Int J Mol Sci 2022; 23: 2358. doi: 10.3390/ijms23042358
- Johnson AB, Richter GT. Surgical considerations in vascular malformations. Tech Vasc Interv Radiol 2019; 22: 100635. doi: 10.1016/J.TVIR.2019.100635
- Penington A, Phillips RJ, Sleebs N, Halliday J. Estimate of the prevalence of vascular malformations. JoVA 2023; 4: e068. doi: 10.1097/JOVA.0000000000000068
- Berger S, Andersen R, Smaastuen MC, Rosseland LA, Dorenberg E. Longterm changes of health-related quality of life in patients with peripheral vascular malformations – a prospective observational study. J Plast Reconstr AesthetSurg 2023; 77: 46-53. doi: 10.1016/j.bjps.2022.10.024
- Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, et al. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet 2015; 97: 914-21. doi: 10.1016/J.AJHG.2015.11.011
- Hage AN, Beecham Chick JF, Srinivasa RN, Bundy JJ, Chauhan NR, Acord M, et al. Treatment of venous malformations: the data, where we are, and how it is done. Tech Vasc Interv Radiol 2018; 21: 45-54. doi: 10.1053/J.TVIR.2018.03.001
- Sadick M, Wohlgemuth WA, Huelse R, Lange B, Henzler T, Schoenberg SO, et al. Interdisciplinary management of head and neck vascular anomalies: clinical presentation, diagnostic findings and minimalinvasive therapies. Eur J Radiol Open 2017; 4: 63-8. doi: 10.1016/J.EJRO.2017.05.001
- De Maria L, De Sanctis P, Balakrishnan K, Tollefson M, Brinjikji W. Sclerotherapy for venous malformations of head and neck: systematic review and meta-analysis. Neurointervention 2020; 15: 4-17. doi: 10.5469/NEUROINT.2019.00213
- Kane G, Fernandez-Pineda I. Targeted therapies for vascular malformations. Front Med (Lausanne) 2024; 11: 1446046. doi: 10.3389/FMED.2024.1446046/TEXT
- Morin G, Galasso I, Canaud G. Vascular malformations: from genetics to therapeutics. EMBO Mol Med 2025; 18: 1-21. doi: 10.1038/S44321-025-00344-X
- McMorrow L, Shaikh M, Kessell G, Muir T. Bleomycin electrosclerotherapy: new treatment to manage vascular malformations. Br J Oral Maxillofac Surg 2017; 55: 977-9. doi: 10.1016/J.BJOMS.2017.10.002
- Michailidis A, Tsifountoudis I, Perdikakis E, Fragkos G, Furmaga-Rokou O, Koutoukoglou P, et al. Electrochemotherapy in the management of vascular malformations: an updated systematic review. Clin Pract 2025; 16: 6. doi: 10.3390/clinpract16010006
- Obereisenbuchner F, Borisch E, Puhr-Westerheide D, Deniz S, Cay Ferdi, Schirren M, et al. Safety and clinical outcome of Bleomycin-Electrosclerotherapy (BEST) treating lymphatic malformations (LMs). Cardiovasc Intervent Radiol 2025; 48: 1428-37. doi: 10.1007/S00270-025-04169-6
- Guida E, Boscarelli A, Zovko Z, Peric-Anicic M, Iaquinto M, Scarpa MG, et al. Bleomycin electrosclerotherapy for peripheral low-flow venous and lymphatic malformations in children: a monocentric case series. Children 2025; 12: 1167. doi: 10.3390/children12091167
- Haehl J, Haeberle B, Muensterer O, Hartel A, Fröba-Pohl A, Dussa CU, et al. Bleomycin electrosclerotherapy (BEST) of slow-flow vascular malformations (SFVMs) in children. J Pediatr Surg 2025; 60: 162631. doi: 10.1016/J.JPEDSURG.2025.162631
- Obereisenbuchner F, Schmidt VF, Goldann C, Brill R, Puhr-Westerheide D, Borisch E, et al. Combining reversible electroporation and bleomycin in treatment of arteriovenous malformations. Cardiovasc Intervent Radiol 2025; 48: 1632-37. doi: 10.1007/S00270-025-04178-5
- Wohlgemuth WA, Müller-Wille R, Meyer L, Wildgruber M, Guntau M, Heydt S von der, et al. Bleomycin electrosclerotherapy in therapy-resistant venous malformations of the body. J Vasc Surg Venous Lymphat Disord 2021; 9: 731-9. doi: 10.1016/J.JVSV.2020.09.009
- Muir T, Wohlgemuth WA, Cemazar M, et al. Current Operating Procedure (COP) for Bleomycin ElectroScleroTherapy (BEST) of low-flow vascular malformations. Radiol Oncol 2024; 57: 141-9. doi: 10.2478/RAON-2023-0029
- Campelo SN, Huang PH, Buie CR, Davalos R V. Recent advancements in electroporation technologies: from bench to clinic. Annu Rev Biomed Eng 2023; 25: 77-100. doi: 10.1146/ANNUREV-BIOENG-110220-023800
- Miklavčič D, Mali B, Kos B, Heller R, Serša G. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online 2014; 13: 29. doi: 10.1186/1475-925X-13-29
- Yarmush ML, Golberg A, Serša G, Kotnik T, Miklavčič D. Electroporationbased technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng 2014; 16: 295-320. doi: 10.1146/annurev-bioeng-071813-104622
- Morozas A, Malyško-Ptašinskė V, Nemeikaitė-Čėnienė A, Kulbacka J, Rembiałkowska N, Ivaška J, et al. Cytotoxic agents for electrochemotherapy: efficacy, mechanisms of action, potential candidates. Biomed Pharmacother 2025; 191: 118451. doi: 10.1016/J.BIOPHA.2025.118451
- Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010; 10: 729-46. doi: 10.1586/ERA.10.43
- Markelc B, Sersa G, Cemazar M. Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels. PLoS One 2013; 8: 1-11. doi: 10.1371/journal.pone.0059557
- Bellard E, Markelc B, Pelofy S, Le Guerroué F, Sersa G, Teissié J, et al. Intravital microscopy at the single vessel level brings new insights of vascular modification mechanisms induced by electropermeabilization. J Control Release 2012; 163: 396-403. doi: 10.1016/j.jconrel.2012.09.010
- Ognard J, Alateya A, El Hajj G, Bisdorff A, Tselikas L, Ayad A, et al. Simply the (B)EST: what the interventionalist needs to know about (bleomycin) electrosclerotherapy for vascular anomalies. Eur Radiol 2025. [Ahead of print]. doi: 10.1007/s00330-025-12077-z
- Colletti G, Rozell-Shannon L, Nocini R. MEST: modified electrosclerotherapy to treat AVM (extracranial arterio-venous malformations). Better than BEST. J Craniomaxillofac Surg 2025; 53: 391-8. doi: 10.1016/J.JCMS.2025.01.004
- Guntau M, Cucuruz B, Brill R, Bidakov O, Von der Heydt S, Deistung A, et al. Individualized treatment of congenital vascular malformations of the tongue. Clin Hemorheol Microcirc 2023; 83: 421-9. doi: 10.3233/CH-221683
- Muir T, Bertino G, Groselj A, Ratnam L, Kis E, Odili J, et al. Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report. Radiol Oncol 2023; 57: 141-9. doi: 10.2478/RAON-2023-0029
- Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008; 98: 388-98. doi: 10.1038/sj.bjc.6604168
- Bigi L, Galdo G, Cesinaro AM, Vaschieri C, Marconi A, Pincelli C, et al. Electrochemotherapy induces apoptotic death in melanoma metastases: a histologic and immunohistochemical investigation. Clin Cosmet Investig Dermatol 2016; 9: 451-9. doi: 10.2147/CCID.S115984
- Schmidt VF, Cangir Ö, Meyer L, Goldann C, Hengst S, Brill R, et al. Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children. Eur Radiol 2024; 34: 6425-34. doi: 10.1007/s00330-024-10723-6
- Larionov A, Hammer CM, Fiedler K, Filgueira L. Dynamics of endothelial cell diversity and plasticity in health and disease. Cells 2024; 13: 1276. doi: 10.3390/CELLS13151276
- Pasut A, Becker LM, Cuypers A, Carmeliet P. Endothelial cell plasticity at the single-cell level. Angiogenesis 2021; 24: 311-26. doi: 10.1007/S10456-021-09797-3
- Filippini A, Tamagnone L, D’Alessio A. Endothelial cell metabolism in vascular functions. Cancers 2022; 14: 1929. doi: 10.3390/CANCERS14081929
- Marziano C, Genet G, Hirschi KK. Vascular endothelial cell specification in health and disease. Angiogenesis 2021; 24: 213-36. doi: 10.1007/S10456-021-09785-7
- Schonning MJ, Koh S, Sun RW, Richter GT, Edwards AK, Shawber CJ, et al. Venous malformation vessels are improperly specified and hyperproliferative. PLoS One 2021; 16: e0252342. doi: 10.1371/JOURNAL.PONE.0252342
- Uebelhoer M, Boon LM, Vikkula M. Vascular anomalies: from genetics toward models for therapeutic trials. Cold Spring Harb Perspect Med 2012; 2: a009688. doi: 10.1101/cshperspect.a009688
- Castillo SD, Tzouanacou E, Zaw-Thin M, Berenjeno IM, Parker VER, Chivite I, et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Sci Transl Med 2016; 8: 332ra43. doi: 10.1126/scitranslmed.aad9982
- Stoodley MA, Morgan MK, Storer KP. Ultrastructural characteristics of hemorrhagic, nonhemorrhagic, and recurrent cavernous malformations. J Neurosurg 2005; 103: 903-9. doi: 10.3171/jns.2005.103.5.0903
- Kaplan S, Ianconetti E, Shapiro-Frank N, Koh S, Clapp A, Shawber CJ, et al. 77. Vascular endothelial growth factor receptor 2 and 3 are mislocalized and fail to respond to flow in venous malformations. Plast Reconstr Surg Glob Open. 2024; 12: 51-2. doi: 10.1097/01.GOX.0001015400.80674.0b
- Uebelhoer M, Nätynki M, Kangas J, Mendola A, Nguyen HL, Soblet J, et al. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet 2013; 22: 3438-48. doi: 10.1093/HMG/DDT198
- Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009; 41: 118-24. doi: 10.1038/ng.272
- Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Sci Transl Med 2016; 8: 332ra42. doi: 10.1126/SCITRANSLMED.AAF1164
- Moneghini L, Tosi D, Graziani D, Caretti A, Colletti G, Baraldini V, et al. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations. Hum Pathol 2020; 99: 98-106. doi: 10.1016/J.HUMPATH.2020.04.001
- Si Y, Huang J, Li X, Fu Y, Xu R, Du Y, et al. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations. Cell Commun Signal 2020; 18: 139. doi: 10.1186/s12964-020-00606-w
- de Melo IG, Tavares V, Pereira D, Medeiros R. Contribution of endothelial dysfunction to cancer susceptibility and progression: a comprehensive narrative review on the genetic risk component. Curr Issues Mol Biol 2024; 46: 4845-73. doi: 10.3390/cimb46050292
- Hida K, Maishi N, Torii C, Hida Y. Tumor angiogenesis—characteristics of tumor endothelial cells. Int J Clin Oncol. 2016; 21: 206-12. doi: 10.1007/s10147-016-0957-1
- De Sanctis F, Ugel S, Facciponte J, Facciabene A. The dark side of tumorassociated endothelial cells. Semin Immunol 2018; 35: 35-47. doi: 10.1016/J.smim.2018.02.002
- Sirico M, D’Angelo A, Gianni C, Casadei C, Merloni F, De Giorgi U. Current state and future challenges for PI3K inhibitors in cancer therapy. Cancers (Basel) 2023; 15: 703. doi: 10.3390/cancers15030703
- Sterba M, Pokorna P, Faberova R, Pinkova B, Skotakova J, Seehofnerova A, et al. Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity. Sci Rep 2023; 13: 10499. doi: 10.1038/s41598-023-37468-4
- Kobialka P, Sabata H, Vilalta O, Gouveia L, Angulo-Urarte A, Muixí L, et al. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. EMBO Mol Med 2022; 14: e15619. doi: 10.15252/EMMM.202115619
- Pang C, Lim CS, Brookes J, Tsui J, Hamilton G. Emerging importance of molecular pathogenesis of vascular malformations in clinical practice and classifications. Vasc Med 2020; 25: 364-77. doi: 10.1177/1358863X20918941
- Annan DAM, Kikuchi H, Maishi N, Hida Y, Hida K. Tumor endothelial cell - a biological tool for translational cancer research. Int J Mol Sci. 2020; 21: 3238. doi: 10.3390/ijms21093238
- Dejana E, Hirschi KK, Simons M. The molecular basis of endothelial cell plasticity. Nat Commun. 2017; 8: 14361. doi: 10.1038/ncomms14361
- Ota T. An updated review on the pathogenesis of brain arteriovenous malformations and its therapeutic targets. J Neuroendovasc Ther 2025; 19: 2024-0008. doi: 10.5797/jnet.ra.2024-0008
- Leone P, Malerba E, Susca N, Favoino E, Perosa F, Brunori G, et al. Endothelial cells in tumor microenvironment: insights and perspectives. Front Immunol 2024; 15: 1367875. doi: 10.3389/fimmu.2024.1367875
- Andersson-Sjöland A, Karlsson JC, Rydell-Törmänen K. ROS-induced endothelial stress contributes to pulmonary fibrosis through pericytes and Wnt signaling. Lab Invest 2016; 96: 206-17. doi: 10.1038/labinvest.2015.100
- Mungunsukh O, Griffin AJ, Lee YH, Day RM. Bleomycin induces the extrinsic apoptotic pathway in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2010; 298: 696-703. doi: 10.1152/ajplung.00322.2009
- Williamson JD, Sadofsky LR, Crooks MG, Greenman J, Hart SP. Bleomycin increases neutrophil adhesion to human vascular endothelial cells independently of upregulation of ICAM-1 and E-selectin. Exp Lung Res 2016; 42: 397-407. doi: 10.1080/01902148.2016.1243742
- Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010; 23: 247-53. doi: 10.3892/OR_00000630
- Zhang W, Chen G, Ren JG, Zhao YF. Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol 2013; 170: 1210-20. doi: 10.1111/bph.12355
- Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371-87. doi: 10.1016/S0305-7372(03)00073-2
- Nevesny F, Chevallier O, Falvo N, Guillen K, Malakhia A, Pellegrinelli J, et al. Bleomycin for percutaneous sclerotherapy of venous and lymphatic malformations: a retrospective study of safety, efficacy and mid-term outcomes in 26 Patients. J Clin Med 2021; 10: 1302. doi: 10.3390/JCM10061302
- Abdelaty MH, Badran AI, Aborahma AM, Elheniedy MA, Kamhawy AH. Intralesional injection of bleomycin in the management of low flow vascular malformations: results and factors affecting the outcome. J Vasc Surg Venous Lymphat Disord 2024; 12: 101694. doi: 10.1016/J.JVSV.2023.101694
- Yamamoto T, Katayama I. Vascular changes in bleomycin-induced scleroderma. Int J Rheumatol 2011; 2011: 270938. doi: 10.1155/2011/270938
- Ohta H, Chiba S, Ebina M, Furuse M, Nukiwa T. Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 302: 193-205. doi: 10.1152/ajplung.00349.2010
- Chen S, Wang Y, Gao Q, Cui J, Shen W. Bleomycin induces endothelial cell pyroptosis and regulates fibrosis by activating the NLRP3/caspase-1/GSDMD pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. J Mol Histol 2024; 55: 1239-50. doi: 10.1007/s10735-024-10264-8
- Cemazar M, Parkins CS, Holder a L, Chaplin DJ, Tozer GM, Sersa G. Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer 2001; 84: 565-70. doi: 10.1054/bjoc.2000.1625
- Serša G, Čemažar M, Miklavčič D. Tumor blood flow modifying effects of electrochemotherapy: a potential vascular targeted mechanism. Radiol Oncol 2003; 37: 43-8.
- Cai Y, Schrenk S, Goines J, Davis GE, Boscolo E. Constitutive active mutant TIE2 induces enlarged vascular lumen formation with loss of apico-basal polarity and pericyte recruitment. Sci Rep 2019; 9: 12352. doi: 10.1038/s41598-019-48854-2
- Goines J, Li X, Cai Y, Mobberley-Schuman P, Metcalf M, Fishman SJ, et al. A xenograft model for venous malformation. Angiogenesis 2018; 21: 725-35. doi: 10.1007/s10456-018-9624-7
- Lazovic B, Nguyen HT, Ansarizadeh M, Wigge L, Kohl F, Li S, et al. Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2L914F mutation in endothelial cells. Angiogenesis 2024; 27: 523-42. doi: 10.1007/S10456-024-09925-9
- Pan Z, Yao Q, Kong W, Ma X, Tian L, Zhao Y, et al. Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discovery. Cell Stem Cell 2025; 32: 227-45.e9. doi: 10.1016/J.STEM.2024.10.015
- Arnaoutova I, George J, Kleinman HK, Benton G. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 2009; 12: 267-74. doi: 10.1007/s10456-009-9146-4
- Stahl A, Wu X, Wenger A, Klagsbrun M, Kurschat P. Endothelial progenitor cell sprouting in spheroid cultures is resistant to inhibition by osteoblasts: a model for bone replacement grafts. FEBS Lett 2005; 579: 5338-42. doi: 10.1016/j.febslet.2005.09.005
- Aw WY, Cho C, Wang H, Cooper AH, Doherty EL, Rocco D, et al. Microphysiological model of PIK3CA-driven vascular malformations reveals a role of dysregulated Rac1 and mTORC1/2 in lesion formation. Sci Adv. 2023; 9: eade8939. doi: 10.1126/sciadv.ade8939
- Aw WY, Sawhney A, Rathod M, Whitworth CP, Doherty EL, Madden E, et al. Dysfunctional mechanotransduction regulates the progression of PIK3CA-driven vascular malformations. bioRxiv 2024; 2024: 08.22.609165. doi: 10.1101/2024.08.22.609165
- Polacheck WJ, Kutys ML, Yang J, Eyckmans J, Wu Y, Vasavada H, et al. A non-canonical Notch complex regulates adherens junctions and vascular barrier function. Nature 2017; 552: 258-62. doi: 10.1038/nature24998
- Rivera R, Cespedes A, Cruz JP, Rivera GC, Valencia A, Rouchaud A, et al. Endovascular treatment simulations using a novel in vitro brain arteriovenous malformation model based on three-dimensional printing millifluidic technology. Interv Neuroradiol 2023: 15910199231184605. doi: 10.1177/15910199231184605
- Cleaver O. Mouse models of vascular development and disease. Curr Opin Hematol 2021; 28: 179-88. doi: 10.1097/MOH.0000000000000649
- Du Z, Yu F, You YH, Zhao ZY, Tian ZW, Xiao M, et al. Endothelial TIE2 mutation induced contraction deficiency of vascular smooth muscle cells via phenotypic transition regulation in venous malformations. Int J Med Sci 2025; 22: 2518-32. doi: 10.7150/IJMS.102700
- Le Cras TD, Goines J, Lakes N, Pastura P, Hammill AM, Adams DM, et al. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation. Angiogenesis 2020; 23: 425-42. doi: 10.1007/s10456-020-09722-0
- Li X, Cai Y, Goines J, Pastura P, Brichta L, Lane A, et al. Ponatinib combined with rapamycin causes regression of murine venous malformation. Arterioscler Thromb Vasc Biol 2019; 39: 496-512. doi: 10.1161/ATVBAHA.118.312315
- Boscolo E, Limaye N, Huang L, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest 2015; 125: 3491-504. doi: 10.1172/JCI76004
- Schrenk S, Goines J, Boscolo E. A patient-derived xenograft model for venous malformation. J Vis Exp 2020; 2020: 10.3791/61501. doi: 10.3791/61501
- Goines J, Boscolo E. A xenograft model for venous malformation. Methods Mol Biol 2021; 2206: 179-92. doi: 10.1007/978-1-0716-0916-3_13
- Rose ML. Endothelial cells as antigen-presenting cells: role in human transplant rejection. Cell Mol Life Sci 1998; 54: 965-78. doi: 10.1007/S000180050226
- Pace A, Steiner ME, Vercellotti GM, Somani A. Endothelial cell provenance: an unclear role in transplant medicine. Front Transplant 2023; 2: 1130941. doi: 10.3389/frtra.2023.1130941
- Wang S, Zhang C, Wang J, Yang C, Xu M, Rong R, et al. Endothelial cells in antibody-mediated rejection of kidney transplantation: pathogenesis mechanisms and therapeutic implications. J Immunol Res 2017; 2017: 8746303. doi: 10.1155/2017/8746303